• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    AIM ImmunoTech And 3 Other Stocks Under $3 Insiders Are Buying

    3/25/24 6:33:28 AM ET
    $AIM
    $BCOV
    $CIA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    EDP Services
    Technology
    Get the next $AIM alert in real time by email

    The Dow Jones index closed lower by over 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

    Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

    Citizens

    • The Trade: Citizens, Inc. (NYSE:CIA) President and CEO Gerald Shields acquired a total of 17,466 shares an average price of $2.26. To acquire these shares, it cost around $39,475.
    • What’s Happening: On March 18, Citizens, named Jon Stenberg as President of Citizens.
    • What Citizens Does: Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States.

    AIM ImmunoTech

    • The Trade: AIM ImmunoTech Inc. (NYSE:AIM) Director Nancy Bryan acquired a total of 38,462 shares at at an average price of $0.39. To acquire these shares, it cost around $15,000.
    • What’s Happening: On Feb. 8, AIM ImmunoTech reported topline results from Phase 2 study evaluating ampligen for the treatment of post-COVID conditions.
    • What AIM ImmunoTech Does: AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases.

    Check This Out: Top 5 Consumer Stocks That May Crash This Month

    Power Solutions International

    • The Trade: Power Solutions International, Inc. (OTC:PSIX) 10% owner Neil Gagnon acquired a total of 5,392 shares at an average price of $2.00. The insider spent around $10,784 to buy those shares.
    • What’s Happening: On March 14, Power Solutions International announced fourth quarter and full year 2023 financial results.
    • What Power Solutions International Does: Power Solutions International Inc is an America-based company that manufactures, distributes, and services power systems that primarily run on nondiesel fuels, including natural gas, propane, and gasoline.

    Brightcove

    • The Trade: Brightcove Inc. (NASDAQ:BCOV) 10% owner Brolin Jonathan acquired a total of 30,000 shares at an average price of $1.88. The insider spent around $56,250 to buy those shares.
    • What’s Happening: On Feb. 22, Brightcove reported fourth-quarter financial results and issued FY24 guidance below estimates.
    • What Brightcove Does: Brightcove Inc is a provider of cloud-based streaming technology and services.

     

    Don’t forget to check out our premarket coverage here

    Get the next $AIM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIM
    $BCOV
    $CIA

    CompanyDatePrice TargetRatingAnalyst
    Brightcove Inc.
    $BCOV
    11/5/2024$3.50Hold → Buy
    Lake Street
    Brightcove Inc.
    $BCOV
    7/31/2023Hold → Buy
    Lake Street
    Brightcove Inc.
    $BCOV
    2/13/2023$8.00 → $10.00Neutral → Buy
    Rosenblatt
    Brightcove Inc.
    $BCOV
    9/9/2022$8.00Neutral
    Rosenblatt
    Brightcove Inc.
    $BCOV
    2/17/2022$14.00 → $9.00Buy → Hold
    Lake Street
    Brightcove Inc.
    $BCOV
    10/28/2021$23.00Outperform → Market Perform
    Northland Capital
    Brightcove Inc.
    $BCOV
    10/28/2021Outperform → Market Perform
    Northland Capital Markets
    Citizens Inc.
    $CIA
    7/19/2021$6.70 → $8.40Neutral → Buy
    Goldman Sachs
    More analyst ratings

    $AIM
    $BCOV
    $CIA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering

    This press release is issued solely to correct a date from an AIM press release dated February 11, 2026. The Subscription Rights will expire if they are not exercised by 5:00 p.m., Eastern Time, on February 27, 2026, the expected expiration date of the Rights Offering. OCALA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) – AIM ImmunoTech Inc. ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced that it has commenced its previously disclosed rights offering (the "Rights Of

    2/12/26 4:35:00 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event

    Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, February 19th at 4:00 PM ET Event to focus on lead program, Ampligen, for treatment of pancreatic cancer OCALA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM, will participate in a Virtual Investor Closing Bell Event on Thursday, February 19, 2026, at 4:00 PM ET. Equels will focus on AIM's clinical and regulatory strategy for its lead drug Ampligen, with an emphasis on the ongoing DURIPANC clinical trial in collaboration with AstraZeneca combining Ampligen and AstraZeneca

    2/12/26 8:55:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AIM ImmunoTech Announces Commencement of Rights Offering

    OCALA, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) – AIM ImmunoTech Inc. ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced that it has commenced its previously disclosed rights offering (the "Rights Offering").  Pursuant to the Rights Offering, the Company is distributing to all holders of record of the Company's common stock, par value $0.001 per share ("Common Stock"), and to holders of certain options and warrants that have the right to participate in the Rights O

    2/11/26 8:30:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    $BCOV
    $CIA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Chemerow David I. was granted 2,800 shares (SEC Form 4)

    4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

    2/6/26 5:03:20 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Taylor Mary increased direct ownership by 1% to 48,364 units (SEC Form 5)

    5 - CITIZENS, INC. (0000024090) (Issuer)

    1/30/26 10:29:36 AM ET
    $CIA
    Life Insurance
    Finance

    Davis Cynthia H increased direct ownership by 0.93% to 45,967 units (SEC Form 5)

    5 - CITIZENS, INC. (0000024090) (Issuer)

    1/30/26 10:28:28 AM ET
    $CIA
    Life Insurance
    Finance

    $AIM
    $BCOV
    $CIA
    SEC Filings

    View All

    SEC Form 424B4 filed by AIM ImmunoTech Inc.

    424B4 - AIM ImmunoTech Inc. (0000946644) (Filer)

    2/17/26 8:15:30 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by AIM ImmunoTech Inc.

    EFFECT - AIM ImmunoTech Inc. (0000946644) (Filer)

    2/11/26 12:15:22 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form S-1/A filed by AIM ImmunoTech Inc.

    S-1/A - AIM ImmunoTech Inc. (0000946644) (Filer)

    2/10/26 4:35:37 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    $BCOV
    $CIA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Stenberg Jon bought $66,407 worth of Citizens (19,914 units at $3.33), increasing direct ownership by 11% to 198,930 units (SEC Form 4)

    4 - CITIZENS, INC. (0000024090) (Issuer)

    6/18/25 2:42:21 PM ET
    $CIA
    Life Insurance
    Finance

    President & CEO Stenberg Jon bought $129,268 worth of Citizens (34,850 units at $3.71), increasing direct ownership by 20% to 179,016 units (SEC Form 4)

    4 - CITIZENS, INC. (0000024090) (Issuer)

    6/2/25 9:53:01 AM ET
    $CIA
    Life Insurance
    Finance

    Chief Legal Officer Kinlaw Sheryl L bought $8,968 worth of Citizens (2,500 units at $3.59), increasing direct ownership by 4% to 69,289 units (SEC Form 4)

    4 - CITIZENS, INC. (0000024090) (Issuer)

    5/29/25 11:00:11 AM ET
    $CIA
    Life Insurance
    Finance

    $AIM
    $BCOV
    $CIA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Brightcove upgraded by Lake Street with a new price target

    Lake Street upgraded Brightcove from Hold to Buy and set a new price target of $3.50

    11/5/24 9:20:44 AM ET
    $BCOV
    EDP Services
    Technology

    Brightcove upgraded by Lake Street

    Lake Street upgraded Brightcove from Hold to Buy

    7/31/23 11:33:20 AM ET
    $BCOV
    EDP Services
    Technology

    Brightcove upgraded by Rosenblatt with a new price target

    Rosenblatt upgraded Brightcove from Neutral to Buy and set a new price target of $10.00 from $8.00 previously

    2/13/23 7:29:40 AM ET
    $BCOV
    EDP Services
    Technology

    $AIM
    $BCOV
    $CIA
    Leadership Updates

    Live Leadership Updates

    View All

    AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director

    OCALA, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the Company's Board of Directors (the "Board") has, by unanimous vote, appointed David Chemerow as an Independent Director to the Board, effective immediately. Mr. Chemerow brings more than 40 years of finance, accounting and operations leadership experience across multiple industries. He previously served as the Chief Financial Officer and Treasurer, and prior to that as Chief Revenue Officer, of Comscore, Inc., an American-based global media measurement and analytics company. Prior to his tenure at Comscore, Mr. Chemerow served as the Chief Operating Officer an

    2/26/25 8:30:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card "FOR" All Four Incumbent Board Members

    Believes Annual Meeting Outcome is Critical to Future of the Company and that the Current Board is Best Positioned to Continue Clinical Trial Momentum, Commercialize Ampligen and Deliver Long-Term Value for Shareholders In AIM's View, the Activist Group's Plan to Reimburse Individuals More Than $5 Million for Failed Attempts to Gain Control of the Board – Without Putting this to a Shareholder Vote – Is Grossly Irresponsible and Not in the Best Interests of All Shareholders Reminds Shareholders that Both Leading Independent Proxy Advisory Firms – ISS and Glass Lewis – Recommended Against Giving the Dissident Nominees Control of the AIM Board, Specifically Citing Their Lack of a Plan, Amo

    12/12/24 3:00:00 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kellner Group Announces Support from Another Former AIM Senior Executive

    Follows Announcement Earlier this Week that Ampligen Co-Founder and Former AIM CEO Agreed to Join Scientific Advisory Board if Kellner Group Nominees Are Elected Kellner Group Reiterates Plan to Revitalize AIM, Accelerate Clinical Development and Restore Value for StockholdersKellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with Stockholders NEW YORK, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney (collectively, the "Kellner Group," "we" or "us" and, as nominees, t

    12/12/24 8:16:14 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    $BCOV
    $CIA
    Financials

    Live finance-specific insights

    View All

    AIM ImmunoTech Announces Stock Dividend

    OCALA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) --  AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced a stock dividend of one share of common stock for every 1,000 shares of outstanding common stock as well as one share of common stock for every outstanding option or warrant that has a right to receive stock dividends ("Alternate Securities"). The dividend will be issuable to stockholders and Alternate Securities holders of record at the close of business on January 9, 2026 and will be distributed and allocated to DTCC on January 13, 2026. Resulting fractional shares will be rounded down and any resulting fractional shares remaining after the foregoing rounding down will

    12/30/25 5:10:00 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

    Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space Expected milestones over the course of the next 18 months provide significant value-driving opportunities, including some trials being partially funded by collaborators AstraZeneca (pancreatic cancer) and Merck (advanced ovarian cancer) Company to host conference call and webcast on Tuesday, April 1st at 8:30 AM ET OCALA, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported its financial results for the fourth quarter and full year 2024 and provided a business

    3/27/25 8:05:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Brightcove Enters into Definitive Agreement to be Acquired by Bending Spoons for $233 Million

    Brightcove Stockholders to Receive $4.45 Per Share in Cash Bending Spoons enters the enterprise SaaS market and will draw on its technology expertise to further strengthen Brightcove and bring its cutting-edge platform to new heights Brightcove Inc. (NASDAQ:BCOV), the world's most trusted streaming technology company, today announced that it has entered into a definitive agreement to be acquired by Bending Spoons, in an all-cash transaction valued at approximately $233 million. Under the terms of the agreement, Brightcove shareholders will receive $4.45 per share in cash for each share of Brightcove common stock that they own. The per share purchase price represents a 90% premium over B

    11/25/24 8:00:00 AM ET
    $BCOV
    EDP Services
    Technology

    $AIM
    $BCOV
    $CIA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

    SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

    12/17/24 4:11:23 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Brightcove Inc.

    SC 13G - BRIGHTCOVE INC (0001313275) (Subject)

    12/3/24 5:05:52 PM ET
    $BCOV
    EDP Services
    Technology

    SEC Form SC 13G filed by AIM ImmunoTech Inc.

    SC 13G - AIM ImmunoTech Inc. (0000946644) (Subject)

    11/14/24 3:21:36 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care